Please assess the completion status of the following clinical trial:

Trial Title: Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Axillary lymph node dissection within the preceding 12 months~Exclusion Criteria:~* Patients with active cancer~* Patients with lymphedema~* Infection or bleeding tendency~* Patients with medical contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs), including history of allergies, know gastrointestinal intolerance~* Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate~* Persons not competent to consent~* Patients on aspirin therapy~* Minors (\< 18 years of age)~* Pregnant and/or lactating women~* Males

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (RS)2-(3-benzoylphenyl)-propionic acid (Type: EXPERIMENTAL): Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed.
- placebo for study drug (Type: PLACEBO_COMPARATOR): Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).